United States Patent 7,842,699: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
United States Patent 7,842,699, titled "Pyrrolo[2,3-d]pyrimidine compounds," was granted to Pfizer Inc. on November 30, 2010. This patent is part of a broader family of patents related to pyrrolo[2,3-d]pyrimidine compounds, which are significant in the field of pharmaceuticals, particularly for treating immune diseases.
Inventors and Assignee
The inventors listed on the patent include Todd A. Blumenkopf, Mark E. Flanagan, and Michael J. Munchhof, among others. The assignee of the patent is Pfizer Inc., a major pharmaceutical company based in Madison, New Jersey[2].
Background and Prior Art
The patent builds upon a series of earlier patent applications and grants, starting from a provisional application filed on December 10, 1999. The patent is a continuation of several non-provisional patent applications, including those filed on August 13, 2003, June 23, 2006, and July 27, 2007. This chain of continuations indicates a long-term research and development effort in the area of pyrrolo[2,3-d]pyrimidine compounds[2].
Claims
The patent includes 18 claims, which define the scope of the invention. These claims cover various aspects of the pyrrolo[2,3-d]pyrimidine compounds, including their chemical structures, methods of preparation, and uses in treating immune diseases. Here are some key claims:
- Claim 1: This claim defines the general structure of the pyrrolo[2,3-d]pyrimidine compounds.
- Claims 2-5: These claims specify various substituents and modifications to the core structure.
- Claims 6-10: These claims cover different methods for preparing the compounds.
- Claims 11-18: These claims relate to the use of these compounds in treating immune diseases and other therapeutic applications[2].
Scope of the Invention
The scope of the invention is broad, encompassing a wide range of pyrrolo[2,3-d]pyrimidine compounds. The patent describes these compounds as having potential therapeutic uses, particularly in treating immune diseases. The scope also includes various methods for synthesizing these compounds and their pharmaceutical compositions.
Patent Term and Adjustments
The patent is subject to a terminal disclaimer, which is a common practice to overcome obviousness-type double patenting (ODP) rejections. This means that the patent term is adjusted to ensure that it does not extend beyond the term of an earlier related patent. The patent term extension under 35 U.S.C. ยง 154(b) is zero days, indicating no additional term adjustment beyond the standard patent term[2].
Related Patents and Continuations
The patent is part of a large family of related patents, including U.S. Patents 6,956,041, 7,265,221, 7,091,208, and 7,601,727, among others. These patents are continuations or divisions of earlier applications, reflecting a comprehensive and ongoing research effort in this area[2].
International Classification
The patent is classified under various international classifications, including A61K 31/59, A61P 37/00, and C07D 487/04, which indicate its relevance to pharmaceutical compositions and therapeutic uses[2].
Search and Analysis Tools
For researchers and practitioners, tools like the USPTO's Patent Claims Research Dataset and the Global Dossier service can be invaluable. These tools provide detailed information on claims, claim-level statistics, and document-level statistics, helping to analyze the patent landscape and identify related applications[3][4].
Patent Landscape
The patent landscape for pyrrolo[2,3-d]pyrimidine compounds is complex and highly competitive. Pfizer Inc.'s patent is one of many in this area, with other pharmaceutical companies also holding related patents. The ongoing research and development in this field are driven by the potential therapeutic benefits of these compounds.
Competitive Analysis
To understand the competitive landscape, one can use tools like the Common Citation Document (CCD) application, which consolidates prior art cited by multiple patent offices. This helps in visualizing the search results for the same invention across different offices and identifying key players in the field[4].
Future Developments
Given the therapeutic potential of pyrrolo[2,3-d]pyrimidine compounds, future developments are likely to focus on further optimizing these compounds for specific diseases and expanding their therapeutic applications. This could involve new patent filings, continuations, and divisions as researchers explore different aspects of these compounds.
Key Takeaways
- Broad Scope: The patent covers a wide range of pyrrolo[2,3-d]pyrimidine compounds and their therapeutic uses.
- Terminal Disclaimer: The patent is subject to a terminal disclaimer to overcome ODP rejections.
- Related Patents: It is part of a large family of related patents, indicating comprehensive research.
- Therapeutic Potential: The compounds have significant potential in treating immune diseases.
- Competitive Landscape: The field is highly competitive, with multiple players holding related patents.
FAQs
What is the main subject of United States Patent 7,842,699?
The main subject of United States Patent 7,842,699 is pyrrolo[2,3-d]pyrimidine compounds, specifically their structures, methods of preparation, and therapeutic uses.
Who are the inventors and assignee of the patent?
The inventors include Todd A. Blumenkopf, Mark E. Flanagan, and Michael J. Munchhof, among others. The assignee is Pfizer Inc.
What is the significance of the terminal disclaimer in this patent?
The terminal disclaimer ensures that the patent term does not extend beyond the term of an earlier related patent, overcoming obviousness-type double patenting (ODP) rejections.
How can one analyze the patent landscape for pyrrolo[2,3-d]pyrimidine compounds?
Tools like the USPTO's Patent Claims Research Dataset and the Global Dossier service can be used to analyze the patent landscape, identify related applications, and understand the competitive environment.
What are the potential future developments in this field?
Future developments are likely to focus on optimizing these compounds for specific diseases and expanding their therapeutic applications, which could involve new patent filings and continuations.
Cited Sources:
- In re Cellect - United States Court of Appeals for the Federal Circuit[1].
- United States Patent 7,842,699 - Blumenkopf et al.[2].
- Patent Claims Research Dataset - USPTO[3].
- USPTO Search Tools - USPTO[4].
